Abstract: The present invention provides a method of identifying a coagulation inhibitor in a sample, comprising: a) contacting a first portion of the sample with a substrate and thrombin; b) contacting a second portion of the sample with a substrate and a2M-thrombin (thrombin caged in alpha-2-macroglobulin); c) contacting a third portion of the sample with a substrate and coagulation factor Xa; d) contacting a fourth portion of the sample with a substrate and a2M-Xa (factor Xa caged in alpha-2-macroglobulin); and e) assaying for cleavage of the substrate in (a), (b), (c) and (d) above, wherein cleavage of the substrate in (b) and (d) and no cleavage in (a) and (c) identifies heparin in the sample; cleavage of the substrate in (a), (b) and (d) and no cleavage in (c) identifies low molecular weight heparin in the sample; cleavage of the substrate in (a) and (b) and no cleavage in (c) and (d) identifies rivaroxaban in the sample, and cleavage of the substrate in (c) and (d) and no cleavage in (a) and (b) identifies dabig

Abstract: Provided is a method of measuring blood coagulation time, the method being capable of LA detection easily and with high sensitivity as compared with the method recommended by the ISTH, without being affected by deficiency of blood coagulation factors even in a blood sample of a warfarin taker, a person who suffers from vitamin K deficiency, or a hepatic failure patient. Disclosed is a method of measuring the blood coagulation time to detect lupus anticoagulant, the method including adding a buffer solution composition containing blood coagulation factors to a blood sample before measurement or at the time of measurement of the blood coagulation time, and measuring the blood coagulation time.

Abstract: A device and kit and method for controlling coagulation in a blood sample. The coagulation controlling agent is at least one of citrate, a protamine salt, its homologs and derivatives, benzamidine, or para-aminobenzamidine. Additives such as water soluble polymers and sugars are also contemplated. The device and kit comprise a container that contains an effective amount of thrombin and a coagulation controlling agent. The method combines thrombin and a coagulation controlling agent to stabilize thrombin or accelerate its activity in a blood sample.

Abstract: Embodiments herein report compositions of alpha-1 antitrypsin fusion polypeptides or peptide derivatives thereof. In certain embodiments, compositions and methods relate to generating a construct of use in pharmaceutically acceptable compositions to treat a subject in need of alpha-1 antitrypsin therapy or treatment. In other embodiments, compositions and methods disclosed herein concern linking alpha-1 antitrypsin or derivative thereof to an immune fragment.

Abstract: Disclosed is a method for measuring clotting time including: preparing a measurement sample by mixing a blood specimen suspected to contain a lupus anticoagulant, an activator, and a divalent-metal-ion-producing compound for facilitating formation of a phospholipid-containing complex; and measuring a clotting time after adding, to the measurement sample, an aqueous solution of a calcium salt as a coagulation initiator.

Abstract: The present invention relates to the in vitro production of erythrocytes/granulocytes and to the treatment of myelodysplastic syndrome using a method for inducing hemoblast differentiation. The present invention provides a media composition comprising gelsolin as an active ingredient for inducing the differentiation of hematopoietic precursor cells into erythrocytes/granulocytes, and a pharmaceutical composition comprising gelsolin as an active ingredient for treating myelodysplastic syndrome. Since the composition of the present invention improves the efficiency of differentiation of hematopoietic precursor cells into erythrocytes/granulocytes while maintaining a low rate of occurrence of cell dysplasia and having the effect of improving the enucleation rate and cell survivability, the present invention can be effectively used for producing erythrocytes/granulocytes in vitro and for treating myelodysplastic syndrome.

Abstract: Methods and kits for measuring levels of von Willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein Ib? having at least two of a G233V, D235Y and M239V mutations and an agent to detect a complex between the recombinant glycoprotein Ib? and von Willebrand factor.

Abstract: A system and method wherein components of a reagent such as labeled antibodies are separated from a biologically active sensor surface by depositing the reagent on a carrier surface distinct from a sensor surface in a detection region. The present device provides a short, well-defined and controlled, pre-incubation time between the particles of interest in the sample fluid and the reagent, thereby increasing the reproducibility by providing all components in one detection region such as a detection chamber.

Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.

Abstract: A method for measuring blood coagulation, including: preparing a reaction solution including a plasma specimen, a blood coagulation activator, and at least one of amino-guanidine and an acid addition salt thereof; and measuring blood coagulation time by detecting a turbidity change in the reaction solution.

Abstract: A presentation module is provided for presenting a fluid sample to a Laser-induced breakdown spectroscopy (LIBS) analysis. The presentation module comprises an inlet for admitting a fluid sample flow from a process flow, a measurement opening for co-operating with measurement optics, and a stabilizer surface facing towards the measurement opening. The stabilizer surface is adapted to form a stabilized sample flow along the stabilizer surface such that the depth and the outer surface of the sample flow are stabilized, and the surface fluctuation and depth variation of the stabilized sample slurry flow are reduced. As laser pulses are focused on the outer surface of the planar sample flow to transform at least a part of the sample into a state of a plasma, the accuracy and repeatability of the LIBS measurement are significantly improved due to the stabilized sample flow.

Abstract: The invention discloses a method for measurement of peptidic degradation products of a proteolytic cascade (for example, the renin-angiotensin system (RAS) and the bradykinin system) in biological samples, especially blood samples, wherein the sample is incubated until a steady state equilibrium is reached for at least one peptidic degradation product involved in said proteolytic cascade and wherein said at least one peptidic degradation product in steady state equilibrium of the proteolytic cascade is quantified in the sample.

Abstract: Test strips for determining the activity of a coagulation factor in a blood sample are provided. The strip comprises a support, a sample inlet port for deposition of a blood sample, and a reaction area comprising a blood coagulation reagent. The sample inlet port is connected to the reaction area, and the coagulation reagent comprises blood plasma deficient in the coagulation factor for which activity is to be measured, an ionic citrate source an ionic calcium source, and either one or more coagulation contact phase activator reagents and phospholipids or a mixture of tissue factor and phospholipids. The disclosure further relates to in vitro methods for measuring an activity of a coagulation factor.

Abstract: A cuvette module comprises a cuvette carrier and a cuvette held by the cuvette carrier. An intermediate chamber is formed in the cuvette carrier. The cuvette carrier comprises an electrically conductive plastic material. The cuvette has a different material than the cuvette carrier and the wettability of the cuvette carrier is greater than the wettability of the cuvette. A method transfers a predetermined amount of liquid from a transport container to a cuvette, employs a cuvette module. The method makes it easier to check whether the intermediate chamber still contains a sufficient amount of liquid.

Abstract: A method for diagnosing von Willebrand disease and novel polypeptides which bind to von Willebrand factor.

Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.

Abstract: The present invention provides a method for producing recombinant prothrombin. The method comprises: providing a vector DNA into which a gene encoding a tag and a gene encoding prothrombin are incorporated, wherein the tag is selected from the group consisting of MBP, SUMO, and NusA; and expressing a tag fusion type prothrombin in a lepidopteran insect or cultured cells of the lepidopteran insect.

Abstract: The invention concerns a method and a system for producing a signal, in particular an electric signal, or a substance having a coagulating or anticoagulant effect. The method is characterized in that it is based on a source substance with coagulating effect, in particular, Ca++ ions, or an anticoagulant affect, in particular heparin. The method consists in: transforming the electromagnetic field derived from said source substance located in the chamber, into a signal, in particular an electric signal, using a transducer-receiver sensing the electromagnetic field; applying to a receiving substance located in the chamber, in particular water or a water-ethanol mixture or homeopathic granules, said signal derived from said transducer-receiver, using a transducer-transmitter. After said treatment, the receiving substance, initially inactive, has a coagulating or anticoagulant effect.

Abstract: The present invention relates to isolated polypeptides having peroxygenase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Abstract: The present invention relates to a photographing control device, microscope and program that can simply confirm whether time lapse photography is being executed normally or not. A number of a display target round, time required for processing of the round, and the operation state of each device of an inverted microscope and a camera in the round, are displayed in a window 431 on a photographed result display screen 421 that displays the photographed result of the time lapse photography. The individual operation time of the each device of the inverted microscope and the camera from the start of the processing of a photographing point selected in a list box 433 to the completion of the photographing of a channel selected in a list box 434, is displayed in a window 435. When an image button is pressed, the image of a photographed sample is displayed. The present invention can be applied to software for controlling time lapse photography using a microscope, for example.

Abstract: The invention relates to a silicon dioxide dispersion that comprises a) an outer flowable phase containing 1) polymerizable monomers, oligomers and/or prepolymers that can be converted to polymers by non-radical reaction; and/or 2) polymers, and b) a disperse phase containing amorphous silicon dioxide. The inventive dispersion is characterized in that the average particle size dmax of the silicon dioxide as measured by small angle neutron scattering (SANS) is between 3 and 50 nm at a maximum half-width of the distribution curve of 1.5 dmax. Such a silicon dioxide dispersion can be easily manufactured even at higher concentrations of the disperse phase and can be used to produce polymer materials that have advantageous properties, especially advantageous mechanical properties.

Abstract: The present invention provides a processing station for automatically processing a biological sample, a system for automated real-time inventory control of consumables within a biological sample handling or assay instrument, a high throughput random access automated instrument for processing biological samples, an automated instrument for processing or analysis of a sample, and processes for automated mucoid detection and elimination. Methods of using the disclosed instruments, mucoid detection processes, and systems to process and/or analyze samples are also disclosed.

Abstract: The present invention provides apparatus and methods for the rapid determination of analytes in liquid samples by immunoassays incorporating magnetic capture of beads on a sensor capable of being used in the point-of-care diagnostic field.

Abstract: A method of measuring the combined activity of both and only coagulation factors II and X for the purpose of monitoring anticoagulant therapy, and kits for using the method. The method involves mixing of test plasma from a human to be tested with specially prepared plasma deficient in both and only coagulation factors II and X but with normal levels of other factors (referred to herein as Fiix-deficient plasma or Fiix plasma), in order to correct for any possible deficiency in other coagulation factors than FII and FX in the test sample. By adding a coagulation reagent and calcium, the generation of thrombin or fibrin can be measured. Kits of the invention comprise a coagulation reagent, calcium and specially made plasma that is deficient in both and only factor II and factor FX.

Abstract: A method is described for the measurement of thrombin activity in the presence of fibrinogen, or for the measurement of the functionality of fibrinogen in the presence of thrombin.

Abstract: Provided is a wound dressing prepared from whole blood that is clotted ex vivo to form a sheet of clotted blood that is applied onto the skin over a sight of skin injury.

Abstract: A test cartridge includes an input channel to receive a liquid sample to be tested. A sample chamber is coupled to the input channel to receive the sample. An air permeable membrane is coupled between the sample chamber and ambient to prevent passage of the sample past the membrane and stop movement of the sample in the sample chamber.

Abstract: The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and/or atherosclerosis.

Abstract: The invention concerns a method for assaying soluble fibrin in a sample, in which said sample is brought into the presence of a plasminogen activator with a high specificity for soluble fibrin (PA-Fb sp) and the soluble fibrin count in the sample is measured by measuring the difference between the count of fibrin degradation products obtained after degrading soluble fibrin with PA-Fb sp and the base count of fibrin degradation products determined before bringing the sample into the presence of PA-Fb sp.

Abstract: The present application provides apparatus and methods for determining the density of a fluid sample. In particular, it provides a sensor device which can be loaded with a fluid sample such as blood, and which further comprises at least one oscillating beam member or resonator. Exposure of the blood sample to clotting agents allows a clotting reaction to commence. The device allows the density of the sample fluid to be monitored with reference to the oscillation of the vibrating beam member, thus allowing the monitoring of the clotting of the fluid sample.

Abstract: A specimen analyzing method and a specimen analyzing apparatus capable of measuring interference substances before analyzing a specimen. The method comprises a step for sucking the specimen stored in a specimen container (150) and sampling it in a first container (153), a step for optically measuring the specimen in the first container, a step for sampling the specimen in a second container (154) and preparing a specimen for measurement by mixing the specimen with a reagent in the second container, and a step for analyzing the specimen for measurement according to the results of the optical measurement of the specimen.

Abstract: An integrated system for determining a hemostasis and oxygen transport parameter of a blood sample, such as blood, is disclosed. The system includes a measurement system, such as an ultrasonic sensor, configured to determine data characterizing the blood sample. For example, the data could be displacement of the blood sample in response to ultrasonic pulses. An integrated aspect of the system may be a common sensor, sample portion or data for fast and efficient determination of both parameters. The parameters can also be used to correct or improve measured parameters. For example, physiological adjustments may be applied to the hemostatic parameters using a HCT measurement. Also, physical adjustments may be applied, such as through calibration using a speed or attenuation of the sound pulse through or by the blood sample. These parameters may be displayed on a GUI to guide treatment.

Abstract: The present invention is directed to compounds useful in stabilizing thrombin activity, thrombin compositions comprising the compounds, methods of using the compounds and methods of identifying compounds capable of stabilizing thrombin activity. The compounds are preferably isolated peptides comprising or interacting with the gamma loop of thrombin.

Abstract: A method for the simultaneous measurement of proteolylic enzyme generation and clot strength in plasma or whole blood or any appropriate biological sample derived from blood. The measurement method encompasses the use of a detectable substrate which includes a moiety that can be released upon reaction with the targeted proteolytic enzyme, and elements for measurement of an increase in viscosity of clot strength.

Abstract: Provided is a method of accurately and easily determining a cause of the prolongation of blood coagulation time.

Abstract: A blood coagulation analysis device and method in which information relating to the coagulability of blood is evaluated based on a change generated in a permittivity measured in a coagulation process of the blood due to addition of a substance that activates or inactivates platelets to the blood.

Abstract: The invention lies in the area of platelet function diagnostics and relates to a method for the determination of platelet function under flow conditions as well as a device for the implementation of this method. The method is particularly suitable for the determination of the effect of clopidogrel and of other P2Y(12) antagonists with antithrombotic activity as well as the determination of P2Y(1) antagonists with antithrombotic activity.

Abstract: A method for sampling a sulphur-containing solid product including supplying a gas flow comprising hydrogen sulphide, bringing the gas flow into contact with a solid reagent and reacting the solid reagent with the hydrogen sulphide contained in the gas flow, the reaction fixing the sulphur of the hydrogen sulphide by forming a sulphur-containing solid product which is different in color from the solid reagent, and recovering the sulphur-containing solid product. The invention also relates to a device suitable for the implementation of this method.

Abstract: A process for preparing a triglyceride composition comprising from 50 to 80% by weight StOSt and from 5 to 20% by weight StOO comprises reacting triolein with stearic acid in the presence of a 1,3-specific lipase from Rhizopus oryzae to form interesterified glycerides and fractionating the interesterified triglycerides.

Abstract: The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides.

Abstract: An exemplary embodiment of the invention may include a method for electrochemically monitoring the mobility of particles in a fluid in response to an external field, the method may include monitoring an electrical characteristic of the fluid in an electrochemical cell, the fluid comprising particles that can be moved under the influence of an externally applied field; observing changes in the electrical characteristic caused by particle movement induced by the external field; and inferring a change in the physical state of the fluid from a change in the magnitude of the electrical characteristic observed.

Abstract: An improved apparatus and method for dispersion of a labeling conjugate in a diagnostic assay, the result being a one-step assay. By eliminating a conjugate pad as in conventional lateral diagnostic devices, and forming a frazil ice pellicle (FIP), rehydration and flow are improved resulting in better reproducibility, improved sensitivity, and reduced costs of individual assay devices. The formation of a frazil ice film formed on a super cooled surface of a sample receiving means simplifies assay assembly. Lyophilization of the FIP improves the release of a sample/analyte/label matrix into a macro channel as in a direct flow assay, while at the same time allowing reagents to mix and flow, thereby optimizing the assay performance. The reagents of the conjugate and the formation of the FIP stabilize the conjugate proteins and provide extended shelf life to the diagnostic assay device.

Abstract: The invention relates to a novel approach and related methods and systems, which provide accurate and easily implemented measurement and analyses of whole blood platelet reactivity, and impact on treatment thereof.

Abstract: The invention discloses a method for measurement of peptidic degradation products of a proteolytic cascade (for example, the renin-angiotensin system (RAS) and the bradykinin system) in biological samples, especially blood samples, wherein the sample is incubated until a steady state equilibrium is reached for at least one peptidic degradation product involved in said proteolytic cascade and wherein said at least one peptidic degradation product in steady state equilibrium of the proteolytic cascade is quantified in the sample.

Abstract: The invention is directed towards methods and compositions for identifying the amount of hydrofluoric acid in a buffered oxide etching composition. In buffered oxide etching compositions it is very difficult to measure the amount of hydrofluoric acid because it has varying equilibriums and it is toxic so it hard to handle and sample. When used to manufacture microchips however, incorrect amounts of hydrofluoric acid will ruin those chips. The invention utilizes a unique method of spectrographically measuring the hydrofluoric acid when in contact with added chromogenic agents to obtain exact measurements that are accurate, immediate, and safe.

Abstract: A homogeneous method for determining the enzymatic activity of an analyte in a sample permits simultaneous determination of the amount of enzyme in the same reaction mixture and determination of enzyme activators or inhibitors.

Abstract: Disclosed are a monoclonal antibody against human D-dimer produced in a mouse and high molecular weight cross-linked fibrin including a corresponding epitope, a cell line secreting the monoclonal antibody, and methods for producing the same. The anti-D-dimer monoclonal antibody of the present invention may be effectively used as a diagnotic agent for screening and detecting in-vivo D-dimer, and high molecular weight cross-linked fibrin and its derivatives containing the D-dimer since the monoclonal antibody specifically reacts with D-dimer, and cross-linked fibrin and its derivatives containing the D-dimer, which do not bind to human fibrinogen or fibrin.

Abstract: An optic light guide test sensor comprises a light guide, a reagent-coated membrane, and a mesh layer. The reagent-coated membrane and the mesh layer are attached to the light guide at an output end of the light guide. The light guide test sensor is adapted to be used to test the level of an analyte in a biological fluid sample when used with a readhead. A method of manufacturing the light guide test sensor involves providing a plurality of light guides, providing a strip of reagent-coated membrane, and providing a strip of mesh layer. The reagent-coated membrane and mesh layer are attached to the light guides by ultrasonic welding. The reagent-coated membrane and mesh layer may also be attached to the light guides by adhesive.

Abstract: The invention is directed towards methods and compositions for identifying the amount of ammonium acid in a buffered oxide etching composition. In buffered oxide etching compositions it is very difficult to measure the amount of ammonium acid because it has varying equilibriums and it is toxic so it hard to handle and sample. When used to manufacture microchips however, incorrect amounts of ammonium acid will ruin those chips. The invention utilizes a unique method of spectrographically measuring the ammonium acid when in contact with added chromogenic agents to obtain exact measurements that are accurate, immediate, and safe.

Abstract: The present invention relates to a chromogenic method for simultaneously determining the activity of multiple coagulation proteases or for simultaneously determining the inhibition of multiple coagulation proteases in a single test reaction. For this purpose, use is made of two chromogenic substrates which have different absorption maxima and whose color signals can be separated spectrally.